Oncology - Hemangiosarcoma Grants
The Oncology - Hemangiosarcoma Research Program Area is designed to gain a better understanding of the biology and progression of this disease with the goal to design new and effective approaches to treatment. Since hemangiosarcoma is often not detected or diagnosed until the later stages of the disease, there is a focus for developing advanced diagnostics as well as therapeutic interventions. Hemangiosarcoma is of major concern to the AKC Canine Health Foundation and has prompted the establishment of an Hemangiosarcoma Research Initiative to uniquely address this disease.
Learn about our Hemangiosarcoma Research Initiative!
Active Grants:
| 03003 | Suppression of Extracellular Glutamate Efflux & mGluR1 Signaling to Impede Canine Hemangiosarcoma Cell Growth |
| 03011 | A GD3 Nano-scaled Liposomal Cancer Vaccine Clinical Trial for Canine Hemangiosarcoma |
| 02946 | Towards Curative Outcomes in Canine Hemangiosarcoma |
| 02806-MOU | Strategic Prevention of Canine Hemangiosarcoma: Lifetime Follow-Up |
| 02746-A | Evaluation of Serum miRNA as a Diagnostic Tool for Canine Splenic Hemangiosarcoma |
| 02534 | Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma |
Previously Awarded Grants:
| 02519 | Prevalence of Bartonella spp. Infection in Dogs with Cardiac and Splenic Hemangiosarcomas within and between Geographic Locations |
| 02942 | Genome-wide Molecular Interrogation of Canine Hemangiosarcoma |
| 02864-A | Luteinizing Hormone Receptor Activation in Canine Hemangiosarcoma Cells |
| 02759-T | Reprogramming the Tumor Immune Niche in Canine Hemangiosarcoma |
| 02510-T | Identification of Novel Synthetic Lethal Partners to Optimize PI3K Targeted Therapies in Canine Hemangiosarcoma |
| 02234-MOU | A Novel Approach for Prevention of Canine Hemangiosarcoma |
| 2217 | A Novel Mechanism to Regulate the Growth of Canine Hemangiosarcoma |
| 01759 | Disrupting the Differentiation of Cancer Stem Cells to Prevent the Spread of Hemangiosarcoma |
| 02081-A | Integrating Cutting Edge Science with Scientific Training to Defeat Hemangiosarcoma |
| 01925-A | Discovery of Novel Micro-Ribonucleic Acids for Diagnosis and Prognosis of Canine Hemangiosarcoma |
| 01911-A | Enhanced Hemangiosarcoma Therapy Using a Novel Combination of Drugs That Target Tumor Proliferation |
| 01429 | Mechanistic Relationship of IL-8 in Cell Proliferation and Survival of Canine Hemangiosarcoma |
| 01131 | Genetic Background and the Angiogenic Phenotype in Cancer |
| 1484 | Identification and Characterization of a Canine Derived Single Chain Antibody that Binds and Neutralizes Canine VEGF |
| 01139 | Immune Targeting of Canine Hemangiosarcoma Using a Canine Derived Single Chain Antibody Approach |
| 01355-A | Expression of Vascular Endothelial markers in Canine Hemangiosarcoma and their use in Diagnostic Cytology Using Immunocytochemistry |
| 01147 | Identifying Mutations in Genes Associated with Canine Hemangiosarcoma |
| 01175-A | Pilot Investigation of the Causes of Hemangiosarcoma in Clumber Spaniels |
| 01168-A | Identifying Mutations in Genes Associated with Canine Hemangiosarcoma: Denser Fine Mapping of the Associated Locus in Chromosome 5 |
| 00257 | Investigation of Predictors of Outcome for Canine Mast Cell Tumors |
| 00593B | Mapping Genes Associated with Canine Hemangiosarcoma |
| 00593A | Mapping Genes Associated with Canine Hemangiosarcoma |
| 01169-A | Identifying Mutations in Genes Associated with Canine Hemangiosarcoma: Denser Fine Mapping of the Associated Locus in Chromosome 26 |
| 422 | Tailored Antitumor Vaccines for Canine Hemangiosarcoma |
| 267 | Investigation into Combined Molecular Approaches to Treat Hemangiosarcoma |
The AKC Canine Health Foundation funds research in 23 different Research Program Areas for the health of all dogs. These program areas enable the Foundation to create depth in our research portfolio and help us to be responsive to the health concerns of our constituents.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
